Tuesday, February 7, 2023

561.316.3330

Biotechnology News Magazine

CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial

Latest Posts

Nectin Therapeutics to Collaborate with Merck on Clinical Trial of Anti-PVR Antibody NTX1088 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced and...

NTX1088 is a First-in-Class and highly potent monoclonal antibody directed against PVR (CD155), a transmembrane protein expressed on cancer cells and associated with resistance to PD1 and PDL1 immune checkpoint inhibitors.

TransCure bioServices Offers BioVolume 3D Imaging for Insightful Preclinical Oncology Research

BioVolume reconstructs tumors from 3D, RGB, and thermal imaging. The solution is non-invasive, using a machine learning algorithm to automatically calculate subcutaneous tumor length, height, and width.

CLINUVEL Drug Significantly Reduces UV Skin Damage

“Today’s results build upon the decades of research CLINUVEL has conducted into the use of afamelanotide to protect skin from light, with the first evidence that a single dose of the drug has a photoprotective effect in healthy volunteers. These data add to our regulatory dossier for XP while further developing our specialised healthcare products for wider populations at highest risk of UV-induced damage and skin cancer,” Dr Bilbao said.

Deciphex Completes Validation Activities Enabling Veterinary Consultant Pathologists to Perform CLP Peer Review Digitally Using Patholytix

GLP and non-GLP studies can now be digitally peer reviewed by consultant pathologists for CROs and Pharma companies leading to faster study review and reduced backlogs with Drug candidates brought to clinical trials sooner advises Deciphex.

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has received regulatory approval from Health Canada allowing inclusion of Canadian sites into the pivotal Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T) randomized, controlled trial.

Richard Whitlock, M.D., Ph.D., FRCSC, Professor of Surgery at McMaster University Medical School and the Population Health Research Institute, Canada Research Chair in Cardiovascular Surgery and Canada Principal Investigator for the STAR-T trial stated, “Canadian cardiac surgery centers are excited to join the STAR-T trial. Ticagrelor is a potent antiplatelet agent with strong evidence of clinical benefit in acute coronary syndromes and is commonly used in the Canadian system. However, managing patients on ticagrelor when they need urgent cardiac surgery is challenging because of the increased bleeding risk. STAR-T will provide definitive evidence whether the DrugSorb-ATR system can effectively remove ticagrelor during surgery and improve clinical outcomes by reducing bleeding. The Population Health Research Institute has successfully completed several of the largest randomized trials in cardiac surgery and will coordinate the STAR-T trial in several of their most successful collaborating sites in Canada. These centers will provide high volume recruitment with high quality data to help answer this important question in a timely manner. Canada is excited to begin recruitment in the pivotal STAR-T trial.”

Dr. Efthymios N. Deliargyris, Chief Medical Officer of CytoSorbents commented, “We are very pleased to receive regulatory approval to expand STAR-T into Canada and are now working closely with our partners at the Population Health Research Institute to onboard up to 7 Canadian sites as soon as possible. We anticipate these high performing sites will contribute meaningfully to study enrollment and help us execute on our stated goals of reaching the next milestones of 80 enrolled patients this Spring and full enrollment of 120 patients by Summer 2023.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine